- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapies targeting stimulatory pathways and beyond
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-13
DOI
10.1186/s13045-021-01085-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor Microenvironment, Metabolism, and Immunotherapy
- (2020) Ralph J. DeBerardinis NEW ENGLAND JOURNAL OF MEDICINE
- Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.
- (2020) Peter A. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
- (2020) Anthony B. El-Khoueiry et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
- (2020) Jonathan Wade Goldman et al. JOURNAL OF CLINICAL ONCOLOGY
- A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.
- (2020) Jeffrey Yachnin et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).
- (2020) Drew W. Rasco et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial characterizing the pharmacokinetic profile and NK and CD8+ t cell expansion with n-803, a chimeric IL-15 superagonist, in healthy volunteers.
- (2020) John M. Wrangle et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma.
- (2020) Li Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- 1537P Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
- (2020) N. Halama et al. ANNALS OF ONCOLOGY
- First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors
- (2020) Ravit Geva et al. CANCER
- Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
- (2020) Lillian Siu et al. Journal for ImmunoTherapy of Cancer
- Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy
- (2019) Gilles Berger et al. TRENDS IN MOLECULAR MEDICINE
- NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
- (2019) Arlene O. Siefker-Radtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.
- (2019) Roberto Pili et al. JOURNAL OF CLINICAL ONCOLOGY
- Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.
- (2019) Niels Halama et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
- (2019) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
- (2019) Manish R. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.
- (2019) Khanh Tu Do et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).
- (2019) Salomon M. Stemmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Determination of the recommended phase II dose of birinapant in combination with pembrolizumab: Results from the dose-escalation phase of BPT-201.
- (2019) Russell J. Schilder et al. JOURNAL OF CLINICAL ONCOLOGY
- Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.
- (2019) Peter A. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
- (2019) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
- (2019) Emiliano Calvo et al. JOURNAL OF CLINICAL ONCOLOGY
- Rational design of anti-GITR-based combination immunotherapy
- (2019) Roberta Zappasodi et al. NATURE MEDICINE
- Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
- (2019) Xinyue Qi et al. Nature Communications
- The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- (2019) Anne Månsson Kvarnhammar et al. Journal for ImmunoTherapy of Cancer
- Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
- (2019) Roheena Z. Panni et al. Science Translational Medicine
- Twists and turns to translating 4-1BB cancer immunotherapy
- (2019) Miguel F. Sanmamed et al. Science Translational Medicine
- Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
- (2019) Tessa Knox et al. Scientific Reports
- Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
- (2019) Selena Vigano et al. Frontiers in Immunology
- CD40 Agonist Antibodies in Cancer Immunotherapy
- (2019) Robert H. Vonderheide Annual Review of Medicine
- OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
- (2019) Juan Deng et al. OncoTargets and Therapy
- Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
- (2019) Stefanie R. Mullins et al. Journal for ImmunoTherapy of Cancer
- STING: a master regulator in the cancer-immunity cycle
- (2019) Yuanyuan Zhu et al. Molecular Cancer
- The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
- (2019) Zuzanna Urban-Wojciuk et al. Frontiers in Immunology
- Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors
- (2019) Kimberley M. Heinhuis et al. JAMA Oncology
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
- (2018) Masoud F. Tavazoie et al. CELL
- HDAC inhibitors as epigenetic regulators for cancer immunotherapy
- (2018) Mariarosaria Conte et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.
- (2018) Yongwoo David Seo et al. JOURNAL OF CLINICAL ONCOLOGY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
- (2018) Sonia Pernas et al. LANCET ONCOLOGY
- Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway
- (2018) Yu Yu et al. ONCOGENE
- Prospects of IL-2 in Cancer Immunotherapy
- (2018) Hani Choudhry et al. Biomed Research International
- Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck
- (2018) Robert L. Ferris et al. JAMA Oncology
- Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
- (2018) Jay Friedman et al. Journal for ImmunoTherapy of Cancer
- Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase 2 IMPULSE study
- (2018) M Thomas et al. ANNALS OF ONCOLOGY
- Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma
- (2018) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).
- (2018) Morten Mau Soerensen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.
- (2018) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
- (2018) Ravit Geva et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125.
- (2018) Hani M. Babiker et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
- (2018) Rachel E. Sanborn et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b study of TAK-659 + nivolumab (nivo) in patients (pts) with advanced solid tumors.
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
- (2018) Juneko E. Grilley-Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
- (2018) Ryan J. Sullivan et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase 6 in cancer
- (2018) Ting Li et al. Journal of Hematology & Oncology
- Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
- (2018) David L. Bajor et al. OncoImmunology
- WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy
- (2018) Lillian Sun et al. OncoImmunology
- Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
- (2018) Ben Tran et al. Journal for ImmunoTherapy of Cancer
- The clinical role of the TME in solid cancer
- (2018) Nicolas A. Giraldo et al. BRITISH JOURNAL OF CANCER
- Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
- (2018) Kevin Sek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
- (2018) Michaël Cerezo et al. NATURE MEDICINE
- The potential and promise of IL-15 in immuno-oncogenic therapies
- (2017) Tanya O. Robinson et al. IMMUNOLOGY LETTERS
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma
- (2017) Yao Zhan et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Syk inhibitors in clinical development for hematological malignancies
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy
- (2017) Kenneth A. Jacobson et al. MEDICINAL RESEARCH REVIEWS
- OX40: Structure and function – What questions remain?
- (2017) Jane Willoughby et al. MOLECULAR IMMUNOLOGY
- Ligands of Therapeutic Utility for the Liver X Receptors
- (2017) Rajesh Komati et al. MOLECULES
- HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
- (2017) Rina M. Mbofung et al. Nature Communications
- Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
- (2017) Shawn T. Beug et al. Nature Communications
- Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade
- (2017) Dirk Zboralski et al. Cancer Immunology Research
- Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma
- (2017) Li-Jun Xue et al. Cancer Medicine
- Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
- (2017) Weiqiang Zhou et al. CURRENT MEDICINAL CHEMISTRY
- 4-1BB agonism: adding the accelerator to cancer immunotherapy
- (2016) Cariad Chester et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Interleukin 15: A key cytokine for immunotherapy
- (2016) Manoj Patidar et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
- (2016) Gregory L. Beatty et al. Expert Review of Anticancer Therapy
- Application potential of toll-like receptors in cancer immunotherapy
- (2016) Ming Shi et al. MEDICINE
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Role of IL-2 in cancer immunotherapy
- (2016) Tao Jiang et al. OncoImmunology
- Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer
- (2015) Mariya O. Krisenko et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential
- (2015) Koen van de Ven et al. Immunotherapy
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- (2015) Dass S. Vinay et al. SEMINARS IN CANCER BIOLOGY
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy
- (2015) D. A. Proia et al. Cancer Immunology Research
- MAP Kinase-Interacting Kinases—Emerging Targets against Cancer
- (2014) Sarah Diab et al. CHEMISTRY & BIOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
- (2014) L Zhou et al. LEUKEMIA
- Smac mimetics and innate immune stimuli synergize to promote tumor death
- (2014) Shawn T Beug et al. NATURE BIOTECHNOLOGY
- Liver X receptors in lipid metabolism: opportunities for drug discovery
- (2014) Cynthia Hong et al. NATURE REVIEWS DRUG DISCOVERY
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Histone deacetylases as targets for treatment of multiple diseases
- (2013) Jinhua Tang et al. CLINICAL SCIENCE
- TLR agonists: our best frenemy in cancer immunotherapy
- (2013) Sabina Kaczanowska et al. JOURNAL OF LEUKOCYTE BIOLOGY
- ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
- (2013) Karen Silence et al. mAbs
- Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
- (2012) J. B. Mitchem et al. CANCER RESEARCH
- HDAC4 Governs a Transcriptional Program Essential for Synaptic Plasticity and Memory
- (2012) Richard Sando et al. CELL
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- CD11b/CD18 (Mac-1) Is a Novel Surface Receptor for Extracellular Double-Stranded RNA To Mediate Cellular Inflammatory Responses
- (2012) H. Zhou et al. JOURNAL OF IMMUNOLOGY
- Rationale Behind Targeting Fibroblast Activation Protein-Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy
- (2012) W. N. Brennen et al. MOLECULAR CANCER THERAPEUTICS
- Targeting IAP proteins for therapeutic intervention in cancer
- (2012) Simone Fulda et al. NATURE REVIEWS DRUG DISCOVERY
- Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses
- (2012) Thomas Höfer et al. Frontiers in Immunology
- Double-Edged Role of the CXCL12/CXCR4 Axis in Experimental Myocardial Infarction
- (2011) Elisa A. Liehn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Interleukin-15 biology and its therapeutic implications in cancer
- (2011) Jason C. Steel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- IAP inhibitors enhance co-stimulation to promote tumor immunity
- (2010) Michael Dougan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The tumor microenvironment and its role in promoting tumor growth
- (2008) T L Whiteside ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started